AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26706103
Drug: (177)Lu-girentuximab, 2405
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (177)Lu-girentuximab, 2405 MBq/m(2) intravenously, with retreatment after 3 months at 75% of the previous dose if no persistent toxicity or progressive disease.
Trial: 26706294
Drug: Three-injection intralymphatic
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-injection intralymphatic immunotherapy
Trial: 26708155
Drug: Alectinib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alectinib 600 mg orally twice daily until progression, death, or withdrawal.
Trial: 26708830
Drug: venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: venlafaxine XR monotherapy for up to 16 weeks
Trial: 26709883
Drug: HBV immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV immunoglobulin and complete vaccine
Trial: 26709883
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (lamivudine or tenofovir/emtricitabine) during pregnancy
Trial: 26709883
Drug: Incomplete vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incomplete vaccine
Trial: 26710961
Drug: Lorazepam (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (one or two doses)
Trial: 26710961
Drug: Lorazepam (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (second double dose)
Trial: 26711546
Drug: Cardiac rehabilitation
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac rehabilitation (CR) prescription at discharge
Trial: 26711747
Drug: ABT-493 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-493 (doses ranging from 100 mg to 700 mg)
Trial: 26711747
Drug: ABT-530 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-530 (doses of ≥ 40 mg)
Trial: 26711756
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g Azithromycin (AZI) given during labor
Trial: 26711775
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g doripenem every 8 h
Trial: 26711777
Drug: AFN-1252, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFN-1252, 200 mg given by mouth twice daily
Trial: 26712084
Drug: pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab 10 mg/kg
Trial: 26712084
Drug: pembrolizumab 2
RxNorm normalized name: pembrolizumab 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab 2 mg/kg (in patients with at least 50% PD-L1 expression)
Trial: 26712084
Drug: pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab 10 mg/kg (in patients with at least 50% PD-L1 expression)
Trial: 26712327
Drug: Expensive biologic
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expensive biologic drug
Trial: 26715442
Drug: Chemotherapy-related toxicities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-related toxicities (severe neutropenia grades ≥3)
Trial: 26715442
Drug: Chemotherapy-related toxicities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-related toxicities (fatigue grades ≥3)
Trial: 26715447
Drug: 6-month guided
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month guided weight loss intervention (twice weekly classes and text messaging)
Trial: 26715573
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg orally daily, gemcitabine 1000 mg/m2 intravenously on days 1, 8, 15, and capecitabine 850 mg/m2 orally twice daily on days 1-21.
Trial: 26715573
Drug: Vandetanib 200
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vandetanib 200 mg orally daily (during dose escalation phase).
Trial: 26715573
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of gemcitabine, capecitabine, and vandetanib.
Trial: 26717526
Drug: Citalopram at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram at a dose of 20-60 mg/d for 12 weeks
Trial: 26717906
Drug: Tablet-based e-workbook
RxNorm normalized name: vitamin E Chewable Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based e-workbook for child mental health treatment
Trial: 26718090
Drug: Conservative oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative oxygen therapy (target SpO2 88-92% using the lowest FiO2)
Trial: 26718690
Drug: Seroprevalence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seroprevalence of pertussis antibodies
Trial: 31316836
Drug: Gum Arabic
RxNorm normalized name: Gum arabic
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum Arabic (GA) 30 g/day for 12 weeks
Trial: 26719818
Drug: Biomarker combinations
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker combinations (urinary neutrophil gelatinase lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (l-FABP), interleukin-18 (IL-18))
Trial: 26720423
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/d orally until disease progression, with continuation at discretion after progression.
Trial: 26720423
Drug: Erlotinib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib therapy overall.
Trial: 26720423
Drug: Erlotinib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib therapy in safety population (n = 207).
Trial: 26723501
Drug: Olaparib 400mg
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 400mg bid capsule monotherapy
Trial: 26724322
Drug: B Cell
RxNorm normalized name: B cell antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B Cell Depletion Therapy
Trial: 26725920
Drug: PA32540 (enteric-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg)
Trial: 26729345
Drug: Rituximab/Bendamustine (RB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab/Bendamustine (RB) followed by Rituximab/High-dose Cytarabine (RC)
Trial: 26729653
Drug: Various immunosuppressants
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various immunosuppressants
Trial: 26731755
Drug: 1% topical
RxNorm normalized name: SSD 1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% topical cidofovir cream applied intraanally three times per week for 4 weeks
Trial: 26731755
Drug: 1% topical
RxNorm normalized name: SSD 1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% topical cidofovir cream
Trial: 26734580
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of sorafenib (400 mg twice daily for 28 days) combined with HAIC using CDDP (20 mg/m(2) on days 1 and 8) and 5-FU (330 mg/m(2) continuously on days 1-5 and 8-12) via an implanted catheter system.
Trial: 26735992
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (200 to 250 ml transfusions, 2 consecutive transfusions)
Trial: 26738949
Drug: Sodium restricted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium restricted (<2,500 mg/d)
Trial: 26738949
Drug: Sodium unrestricted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium unrestricted (≥2,500 mg/d)
Trial: 26738949
Drug: Sodium restricted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium restricted (<2,500 mg/d) in patients not receiving ACE inhibitors or ARBs
Trial: 26739732
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg daily for 21 days preoperatively
Trial: 26740893
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day desloratadine for 4 weeks
Trial: 26740893
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day levocetirizine for 4 weeks
Trial: 26740893
Drug: Both H1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both H1 antihistamines
Trial: 26745574
Drug: Placental matrix-derived
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placental matrix-derived mesenchymal stem cells (PM-MSCs) injection
Trial: 26747086
Drug: Anthracycline doses
RxNorm normalized name: methacycline
DrugBank: Metacycline (DB00931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anthracycline doses of 250 mg/m2 or more
Trial: 26748972
Drug: Infanrix hexa
RxNorm normalized name: Infanrix
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infanrix hexa (DTPa-HBV-IPV/Hib) vaccine reimbursement
Trial: 26751952
Drug: Aerobic training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic training on a stationary bike for 30 minutes, three times weekly, for 10 weeks at 70% of VO2max.
Trial: 26752024
Drug: Doubling dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling dose of Salmeterol and Fluticasone Propionate for 10 days
Trial: 26752024
Drug: Antibiotic for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic for 5 days (for purulent exacerbations)
Trial: 26753096
Drug: Salivary cortisol
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salivary cortisol (SaC) levels in high STC group on Day 1: 2.3 (0.2-9.0) μg/dL; Day 7: 1.1 (0.8-4.6) μg/dL
Trial: 26753096
Drug: Salivary cortisol
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salivary cortisol (SaC) levels in control group: Baseline: 0.4 (0.1-1.4) μg/dL; Peak: 1.1 (0.4-2.5) μg/dL
Trial: 26753096
Drug: Calculated free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated free cortisol (cFC) levels in high STC group on Day 1: 0.3 (0.1-0.3) μg/dL; Day 7: 0.2 (0.1-0.3) μg/dL
Trial: 26753096
Drug: Calculated free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated free cortisol (cFC) levels in control group: Baseline: 1.7 (0.4-1.9) μg/dL; Peak: 1.8 (1.0-6.6) μg/dL
Trial: 26754175
Drug: Qualitative insights
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative insights from GPs and community members regarding antibiotic prescribing and consumption for UTI.
Trial: 26755520
Drug: Atezolizumab (MPDL3280A)
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab (MPDL3280A) administered intravenously every 3 weeks
Trial: 26755709
Drug: Blinatumomab (stepwise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (stepwise dosing: 9-28-112 μg/d with weekly dose increases)
Trial: 26755709
Drug: Blinatumomab (flat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (flat dosing: 112 μg/d)
Trial: 26755709
Drug: Blinatumomab (stepwise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (stepwise dosing)
Trial: 26755710
Drug: Prophylaxis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis with rIX-FP 40 IU/kg weekly
Trial: 26755710
Drug: On-demand treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand treatment for bleeding episodes
Trial: 26755712
Drug: High-dose daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose daunorubicin (90 mg/m(2))
Trial: 26755712
Drug: Standard-dose daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose daunorubicin (45 mg/m(2))
Trial: 26757786
Drug: Guideline-recommended therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended therapies
Trial: 26758264
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with ≥ 2 of the following characteristics: age ≥ 80 years, anticoagulant therapy, pulmonary disease, pharmacologically treated psychiatric disorder, anaemia, and walking aids
Trial: 26758879
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg daily for 2 years
Trial: 26759992
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of antipsychotic medication (N=46)
Trial: 26759992
Drug: Maintenance on
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance on prescribed antipsychotic medication (N=22)
Trial: 26762363
Drug: High-dose inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inactivated influenza vaccine
Trial: 26762363
Drug: Standard-dose inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose inactivated influenza vaccine
Trial: 26762363
Drug: Enzyme-linked lectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-linked lectin assay for antineuraminidase N2 antibodies
Trial: 26764356
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (50 mg/kg per day on days 3 and 4 after transplantation)
Trial: 26765643
Drug: Standard anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anticoagulation therapy
Trial: 26765645
Drug: Alemtuzumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alemtuzumab (10 mg per day for 10 days)
Trial: 26766736
Drug: PI3K/AKT/mTOR inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI3K/AKT/mTOR inhibitors
Trial: 26767709
Drug: Pipeline Embolization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipeline Embolization Device with concurrent coil embolization
Trial: 26770032
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated zoster vaccine (ZOSTAVAX™, Merck & Co., Inc.)
Trial: 26772734
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/day on a 4-week-on, 2-week-off schedule)
Trial: 26772812
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m², 60 min, d 1) and oxaliplatin (80 mg/m², 120 min, d 2) in 21-day cycles for up to 8 cycles
Trial: 26773712
Drug: (131) I-MIBG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (131) I-MIBG therapy at a dose of 0.67 GBq (18 mCi)/kg/dose
Trial: 26774243
Drug: Single low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single low-dose primaquine
Trial: 26774555
Drug: Panobinostat 20
RxNorm normalized name: panobinostat 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat 20 mg orally 3 times weekly with letrozole 2.5 mg daily
Trial: 26774555
Drug: Panobinostat 30
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat 30 mg orally 3 times weekly with letrozole 2.5 mg daily
Trial: 26777085
Drug: Intraduodenal levodopa-carbidopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal levodopa-carbidopa intestinal gel (LCIG) infusion
Trial: 26777228
Drug: MRI-TULSA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-TULSA treatment
Trial: 26778949
Drug: Hunger sensation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hunger sensation, wanting, liking, and perception of solution's intensity
Trial: 26780395
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (2 capsules of 220 mg each per day for 3 months)
Trial: 26780484
Drug: Tabalumab (BAFF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab (BAFF inhibitor) 240-mg SC at Week 0 followed by 120-mg SC monthly for 5 additional months.
Trial: 26780484
Drug: Tabalumab (BAFF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab (BAFF inhibitor)
Trial: 26781724
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir (ETV) 1.0 mg plus Tenofovir (TDF) 300 mg combination therapy for 48 weeks
Trial: 26781817
Drug: High BCAA
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High BCAA content diet (14.0±0.6 g valine, 13.8±0.5 g isoleucine, 27.1±1.0 g leucine)
Trial: 26781817
Drug: Low BCAA
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low BCAA content diet (1.5±0.1 g valine, 4.5±0.9 g isoleucine, 2.1±0.2 g leucine)
Trial: 26782796
Drug: Nursery songs
RxNorm normalized name: Xian Bei Luo Ye Song Wood
DrugBank: Larix sibirica wood (DB14289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nursery songs intervention; details on dosage and duration not specified.
Trial: 26782971
Drug: UMEC 125 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC 125 μg once daily
Trial: 26784028
Drug: Synthetic thyroid
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic thyroid hormone (levothyroxine)
Trial: 26784028
Drug: Subclinical hyperthyroid
RxNorm normalized name: APurThyroid 90 MG (1 1/2 grain) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subclinical hyperthyroid state (after treatment)
Trial: 26784138
Drug: Midostaurin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin 50 mg bid and escalating doses of bortezomib (1 to 1.3 mg/m2)
Trial: 26784138
Drug: Midostaurin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin and bortezomib following chemotherapy with mitoxantrone, etoposide, cytarabine (MEC)
Trial: 26784704
Drug: Clozapine maintenance
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine maintenance therapy (dosages ranging from 50 to 900 mg, median dosage of 500 mg)
Trial: 26785287
Drug: CC-486 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 (oral azacitidine) maintenance therapy (300 mg/day for 14 days of 28-day treatment cycles)
Trial: 26785742
Drug: Digital quantification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital quantification of B lymphocytes using anti-CD20 antibodies and image analysis.
Trial: 26785742
Drug: Digital quantification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital quantification of T lymphocytes using anti-CD3 antibodies and image analysis.
Trial: 26785742
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of B-cell proportion with clinical and biological activity markers.
Trial: 26787381
Drug: Cerebrospinal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrospinal fluid and urine heparin sulfate levels
Trial: 26790007
Drug: Early loading
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early loading of splinted OsseoSpeed(™) TX implants
Trial: 26790480
Drug: AAV2 neutralizing
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV2 neutralizing antibodies (NAbs)
Trial: 26790480
Drug: AAV8 neutralizing
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV8 neutralizing antibodies (NAbs)
Trial: 26790480
Drug: AAV9 neutralizing
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV9 neutralizing antibodies (NAbs)
Trial: 26793618
Drug: PC +
RxNorm normalized name: aspirin / caffeine / propoxyphene hydrochloride Oral Capsule [PC-CAP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC + D (Pemetrexed at 500 mg/m² and Cisplatin at 75 mg/m² IV every 3 weeks, Dalotuzumab at 10 mg/kg IV weekly on days 1, 8, and 15 of every 3-week cycle)
Trial: 26793618
Drug: PC (Pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC (Pemetrexed at 500 mg/m² and Cisplatin at 75 mg/m² IV every 3 weeks)
Trial: 26793976
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral ART daily for 4 weeks
Trial: 26793976
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oral ART daily for 4 weeks
Trial: 26793976
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral ART daily for 4 weeks
Trial: 26793974
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg/day (phase II)
Trial: 26793974
Drug: Enzalutamide (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (multiple doses in phase I)
Trial: 26794905
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dosing of celgosivir starting on day 0